ES2096624T3 - Composicion revestida y su procedimiento de preparacion. - Google Patents

Composicion revestida y su procedimiento de preparacion.

Info

Publication number
ES2096624T3
ES2096624T3 ES91303256T ES91303256T ES2096624T3 ES 2096624 T3 ES2096624 T3 ES 2096624T3 ES 91303256 T ES91303256 T ES 91303256T ES 91303256 T ES91303256 T ES 91303256T ES 2096624 T3 ES2096624 T3 ES 2096624T3
Authority
ES
Spain
Prior art keywords
heat
ligator
preparation procedure
coated composition
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91303256T
Other languages
English (en)
Inventor
Norboru Nagafuzi
Takayuki Tsukada
Kazuhiro Shima
Yasushi Takagishi
Yusuke Suzuki
Yoshitaka Tomoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2096624T3 publication Critical patent/ES2096624T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN PROCESO PARA PREPARAR UNA COMPOSICION DE REVESTIMIENTO COMPRENDE UNA SUBSTANCIA ACTIVA FARMACEUTICAMENTE ESTABLE AL CALOR, QUE COMPRENDE EL GRANULAR CENTRIFUGAMENTE UNA MEZCLA QUE COMPRENDE DICHA SUBSTANCIA ACTIVA Y UN PRIMER MATERIAL DE FUSION POR CALOR COMO LIGADOR BAJO CALOR SIN LA UTILIZACION DE NINGUN DISOLVENTE Y REVISTIENDO LOS GRANULOS RESULTANTES CON UN SEGUNDO MATERIAL TERMOFUNDIDO COMO UN MATERIAL DE REVESTIMIENTO BAJO CALOR, SIENDO EL PUNTO DE FUSION DEL SEGUNDO MATERIAL TERMOFUNDENTE MAS BAJO QUE EL DEL PRIMER MATERIAL TERMOFUNDENTE.
ES91303256T 1990-04-12 1991-04-12 Composicion revestida y su procedimiento de preparacion. Expired - Lifetime ES2096624T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9666390 1990-04-12

Publications (1)

Publication Number Publication Date
ES2096624T3 true ES2096624T3 (es) 1997-03-16

Family

ID=14171060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91303256T Expired - Lifetime ES2096624T3 (es) 1990-04-12 1991-04-12 Composicion revestida y su procedimiento de preparacion.

Country Status (8)

Country Link
EP (1) EP0452145B1 (es)
JP (1) JP3191948B2 (es)
KR (1) KR0168849B1 (es)
AT (1) ATE145131T1 (es)
DE (1) DE69123075T2 (es)
DK (1) DK0452145T3 (es)
ES (1) ES2096624T3 (es)
GR (1) GR3021606T3 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
FR2705677B1 (fr) * 1993-05-28 1995-08-11 Roquette Freres Micro-granules obtenus par extrusion-sphéronisation contenant une cyclodextrine.
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JP3466921B2 (ja) * 1998-06-03 2003-11-17 大塚製薬株式会社 味マスキング医薬製剤
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
AU1323400A (en) * 1998-10-27 2000-05-15 Fuisz Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
AT407111B (de) 1998-12-22 2000-12-27 Gergely Dr & Co Zucker- und/oder zuckeralkoholhältiges matrixmaterial und verfahren zu seiner herstellung
CA2367373C (en) * 1999-03-17 2011-09-20 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP4658306B2 (ja) * 2000-10-18 2011-03-23 ナガセ医薬品株式会社 錠剤用医薬組成物
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
JP2005298412A (ja) * 2004-04-13 2005-10-27 Minato Pharmaceutical Co Ltd 被覆粒子
US20100068274A1 (en) * 2007-04-26 2010-03-18 Eisai R & D Management Co., Ltd. Process for production of tablet
KR20220124747A (ko) * 2020-03-11 2022-09-14 사와이세이야쿠 가부시키가이샤 과립 및 그것을 이용한 제제
WO2023145865A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用ポリアルキレンオキシド粒子、医薬用組成物、製剤用組成物及び製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
US4940665A (en) * 1985-12-27 1990-07-10 Showa Denko K. K. Method for granulation of enzyme
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
NZ231281A (en) * 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol

Also Published As

Publication number Publication date
KR910018016A (ko) 1991-11-30
JPH04217913A (ja) 1992-08-07
EP0452145B1 (en) 1996-11-13
DK0452145T3 (da) 1996-12-02
GR3021606T3 (en) 1997-02-28
DE69123075T2 (de) 1997-03-20
KR0168849B1 (ko) 1999-01-15
JP3191948B2 (ja) 2001-07-23
ATE145131T1 (de) 1996-11-15
EP0452145A2 (en) 1991-10-16
EP0452145A3 (en) 1993-03-10
DE69123075D1 (de) 1996-12-19

Similar Documents

Publication Publication Date Title
ES2076192T3 (es) Farmacos soportados con proporcion de disolucion incrementada, y un proceso para su preparacion.
ES2111662T3 (es) Mezclas polimericas para revestimiento termosellable para tejados y azoteas y metodo para cubrir tejados y azoteas.
DK0452145T3 (da) Overtrukket præparat og fremstilling deraf
ES2115298T3 (es) Nuevos derivados de 1-fenil-3-dimetil-amino-propano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES528598A0 (es) Procedimiento para la obtencion de adhesivos de fusion para el termoencolado de materias textiles.
EP0642301A4 (en) Pharmaceutically acceptable fixed-dried human blood platelets.
AR225305A1 (es) Procedimiento para la aislacion de una tuberia mediante la aplicacion de material polimerico esponjoso en dos o mas capas
ES493711A0 (es) Procedimiento para la preparacion de una composicion de pig-mento inorganico dispersable
AR219126A1 (es) Procedimiento para la preparacion de polieter-esteramidas secuenciadas por reaccion en estado de fusion de una poliamida dicarboxilica,producto obtenido y aplicacion del mismo
ES524198A0 (es) Un procedimiento para la fabricacion de una composicion plastificada y cargada de interpolimeros de etileno, modificada con agentes tensioactivos.
NO931859D0 (no) Blanding for kontrollert frigjoering av en aktiv bestanddel
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2061609T3 (es) 2',3'-dideoxi-2'-fluoro-nucleosidos.
IT8019071A0 (it) Plicazione terapeutica. derivati del nor-tropano, loro procedimento di preparazione e loro ap
DE69209080D1 (de) Pharmazeutische zusammemsetzungen mit verzoegerter freigabe
MX9102500A (es) Compuestos de bifenilio, procedimiento para su preparacion y composicion farmaceutica que los contiene.
NO153496C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive indolizin-derivater.
MX9202152A (es) Derivados del indol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
AR230431A1 (es) Compuesto de difenileter 3-hidrazin-4-nitro sustituidos y derivados 3-maleinimido,fenilmaleinimido y dihidroisoindolina,procedimiento para su preparacion y herbicidas que los contienen
ES2034951T3 (es) Microgranulados cargados de una substancia activa, constituidos esencialmente por un triglicerido de acidos grasos saturados y su utilizacion por via topica en el campo terapeutico.
ES485168A0 (es) Un procedimiento para la preparacion de una composicion far-maceutica util para el tratamiento de la hipercolesteremia.
ES497128A0 (es) Un procedimiento para la preparacion de una composicion de recubrimiento polimerica.
EA199800593A1 (ru) Микрогранулы с пролонгированным высвобождением, содержащие дилтиазем в качестве активного ингредиента
KR890700020A (ko) 서방성과립 및 그를 함유하는 지속성 복합과립
ES2063412T3 (es) Tableta y granulado que contienen como principio activo mesna.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 452145

Country of ref document: ES